149
Views
2
CrossRef citations to date
0
Altmetric
Original Article

Effects of Ondansetron on Chemotherapy-induced Acute and Delayed Emesis—A Pilot Study

, , , , &
Pages 649-651 | Published online: 08 Jul 2009

References

  • Gralla R J, Itri L M, Pisko S E, et al. Antiemetic efficacy of high-dose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981; 305: 905–9
  • Bruera E D, Roca E, Cedaro L, Chacón R, Estévez R. Improved control of chemotherapy-induced emesis by the addition of dexamethasone to metoclopramide in patients resistant to metoclopramide. Cancer Treat Rep 1983; 67: 381–3
  • Kris M G, Gralla R J, Tyson L B, et al. Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Cancer 1983; 55: 527–34
  • Miner W B, Sanger G J, Turner DH. Evidence that 5-hydroxy-tryptamine, receptors mediate cytotoxic drug and radiation-evoked emesis. Br J Cancer 1987; 56: 159–62
  • Andrews P LR, Rapeport W G, Sanger GJ. Neuropharmacology of emesis induced by anti-cancer therapy. TIPS 1988; 9: 334–41
  • Richardson B P, Engel G, Donatsch P, Stadler PA. Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 1985; 316: 126–31
  • Marty M, Pouillart P, Scholl S, et al. Comparison of the 5-hydroxytryptamine, (serotonin) antagonist ondansetron (GR38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990; 322: 816–21
  • Gralla R J, Kris M G, Tyson L B, Clark RA. Controlling emesis in patients receiving cancer chemotherapy. Recent Results Cancer Res 1988; 108: 89–101
  • Burish T G, Carey M P, Krozely M G, Greco FA. Conditioned side-effects induced by cancer chemotherapy: Prevention through behavioral treatment. J Consult Clin Psychol 1987; 55: 42–8

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.